HIV vaccine development: Strategies for preclinical and clinical investigation

AIDS Research and Human Retroviruses

Volumn 29, Issue 11, 2013, Pages 1401-1406

  Shapiro, Stuart Z ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CLINICAL TRIAL (TOPIC); COST EFFECTIVENESS ANALYSIS; EXPERIMENTAL ANIMAL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; NONHUMAN; PRIORITY JOURNAL; PRODUCT DEVELOPMENT; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS;

AIDS VACCINES; ANIMALS; DRUG DISCOVERY; DRUG EVALUATION; DRUG EVALUATION, PRECLINICAL; HIV INFECTIONS; HUMANS; MODELS, ANIMAL;

EID: 84883446425     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2012.0337     Document Type: Article

References (23)

1. Morgan C, Marthas M, Miller C, et al.: The use of nonhuman primate models in HIV vaccine development. PLoS Med 2008; 5(8): e173.
2. Corey L, Nabel GJ, Dieffenbach C, et al.: HIV-1 vaccines and adaptive trial designs. Sci Transl Med 2011; 3: 79: ps13.
3. Keele BF, Li H, Learn GH, et al.: Low-dose rectal inoculation of rhesus macaques by SIVsmE660 or SIVmac251 recapitulates human mucosal infection by HIV-1. J Exp Med 2009; 206: 1117-1134.
4. Stone M, Keele BF, Ma ZM, et al.: A limited number of simian immunodeficiency virus (SIV) env variants are transmitted to rhesus macaques vaginally inoculated with SIVmac251. J Virol 2010; 84: 7083-7095.
5. Ma ZM, Keele BF, Qureshi H, et al.: SIVmac251 is inefficiently transmitted to rhesus macaques by penile inoculation with a single SIVenv variant found in ramp-up phase plasma. AIDS Res Hum Retroviruses 2011; 27: 1259-1269.
6. Keele BF, Giorgi EE, Salazar-Gonzalez JF, et al.: Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci USA 2008; 105: 7552-7557.
7. Barouch DH, Liu J, Li H, et al.: Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Nature 2012; 482: 89-93.
8. Lai L, Kwa SF, Kozlowski PA, et al.: SIVmac239 MVA vaccine with and without a DNA prime, similar prevention of infection by a repeated dose SIVsmE660 challenge despite different immune responses. Vaccine 2012; 30: 1737-1745.
9. Fukazawa Y, Park H, Cameron MJ, et al.: Lymph node T cell responses predict the efficacy of live attenuated SIV vaccines. Nat Med 2012; 18: 1673-1681.
10. Pantaleo G and Koup RA: Correlates of immune protection in HIV-1 infection: What we know, what we don't know, what we should know. Nat Med 2004; 10: 806-810.
11. Burgers WA, Manrique A, Masopust D, et al.: Measurements of immune responses for establishing correlates of vaccine protection against HIV. AIDS Res Hum Retroviruses 2011; 28: 641-648.
12. Ipsen J: Circulating antitoxin at the onset of diphtheria in 425 patients. J Immunol 1946; 54: 325-347.
13. Enders JF, Kane LW, Cohen S, and Levens JH: Immunity in mumps, I. Experiments with monkeys (Macacus mulatta). The development of complement-fixing antibody following infection and experiments on immunization by means of inactivated virus and convalescent human serum. J Exp Med 1945; 81: 93-117.
14. Kelly S and Dalldorf G: Antigenic potency of poliovirus vaccines. Am J Hyg 1956; 64: 243-258.
15. Sabin AB, Tigertt WD, Ando K, et al.: Evaluation of Japanese B encephalitis vaccine, I. General background and methods. Am J Hyg 1956; 63: 217-227.
16. Johnson CD and Goodpasture EW: Experimental immunity to the virus of mumps in monkeys. Am J Hyg 1936; 23: 329-339.
17. Robbins JB, Parke JC, Schneerson R, and Whisnant JK: Quantitative measurement of ''natural'' and immunizationinduced Haemophilus influenza type b capsular polysaccharide antibodies. Pediat Res 1973; 7: 103-110.
18. Shouval D, Ashur Y, Adler R, et al.: Single and booster dose responses to an inactivated hepatitis A virus vaccine: Comparison with immune serum globulin prophylaxis. Vaccine 1993; 11: S9-S14.
19. Bradstreet CMP, Kirkwood B, Pattison JR, and Tobin JO'H: The derivation of a minimum immune titre of rubella haemagglutinin- inhibition (HI) antibody. A Public Health Laboratory Service collaborative survey. J Hyg 1978; 81: 383-388.
20. Mascola JR, Louder MK, VanCott TC, et al.: Potent and synergistic neutralization of human immunodeficiency virus (HIV) type 1 primary isolates by hyperimmune anti-HIV immunoglobulin combined with monoclonal antibodies 2F5 and 2G12. J Virol 1997; 71: 7198-7206.
21. Mascola JR, Lewis MG, Stiegler G, et al.: Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J Virol 1999; 73: 4009-4018.
22. Hessell AJ, Hangartner L, Hunter M, et al.: Fc receptor but not complement binding is important in antibody protection against HIV. Nature 2007; 449: 101-104.
23. Sharma UK, Schito M, Welte A, et al.: Workshop summary: Novel Biomarkers for HIV Incidence Assay Development. AIDS Res Hum Retroviruses 2012; 28: 532-539.